{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:54:27Z","timestamp":1770062067744,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Omnix Medical Ltd.","award":["80010"],"award-info":[{"award-number":["80010"]}]},{"name":"Omnix Medical Ltd.","award":["82849"],"award-info":[{"award-number":["82849"]}]},{"name":"Israel Innovation Authority","award":["80010"],"award-info":[{"award-number":["80010"]}]},{"name":"Israel Innovation Authority","award":["82849"],"award-info":[{"award-number":["82849"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: People with cystic fibrosis (pwCF) frequently suffer from chronic lung infections, with Pseudomonas aeruginosa being the predominant pathogen contributing to disease progression and morbidity. The increasing prevalence of multi-drug-resistant (MDR) P. aeruginosa has diminished treatment options. Antimicrobial peptides (AMPs) have emerged as promising alternatives to conventional antibiotics due to their unique membrane-targeting mechanisms. OMN51, a novel bioengineered AMP derived from capitellacin, was evaluated for antimicrobial activity against P. aeruginosa in sputum samples from pwCF. This study aimed to compare the bactericidal effects of OMN51 with those of a range of conventional antibiotics known to have activity against P. aeruginosa clinical isolates derived from pwCF. Methods:P. aeruginosa clinical isolates were obtained from fifty-six unique sputum cultures of pwCF at a tertiary-university-affiliated hospital. Minimum inhibitory concentrations (MICs) of OMN51 and comparator antibiotics were determined using broth microdilution. Antimicrobial susceptibility was evaluated using the Kirby\u2013Bauer disc diffusion method. Results: OMN51 demonstrated in vitro bactericidal activity across all P. aeruginosa isolates, including MDR strains. MIC values for OMN51 ranged from 4 to 16 \u00b5g\/mL, with no observed resistance or cross-resistance. Comparative analysis revealed the superior efficacy of OMN51 compared with conventional antibiotics. Conclusions: OMN51 exhibits robust in vitro activity against MDR P. aeruginosa, supporting its candidacy as a therapeutic agent for MDR P. aeruginosa- associated infections. Further studies are warranted to assess pharmacokinetics and in vivo safety and efficacy. OMN51 represents a first-in-class, membrane-targeting therapeutic showing promise against MDR P. aeruginosa.<\/jats:p>","DOI":"10.3390\/jcm14155208","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T10:49:17Z","timestamp":1753267757000},"page":"5208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Vitro Antimicrobial Activity of the Novel Antimicrobial Peptide OMN51 Against Multi-Drug-Resistant Pseudomonas aeruginosa Isolated from People with Cystic Fibrosis"],"prefix":"10.3390","volume":"14","author":[{"given":"Moshe","family":"Heching","sequence":"first","affiliation":[{"name":"Pulmonology Institute and Adult CF Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Street, Petach Tikva 4941492, Israel"},{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe","family":"Cohen-Kutner","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haim","family":"Ben-Zvi","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel"},{"name":"Clinical Microbiology Laboratory, Rabin Medical Center, Beilinson Hospital, Petach Tikva 4941492, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liora","family":"Slomianksy","sequence":"additional","affiliation":[{"name":"Pulmonology Institute and Adult CF Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Street, Petach Tikva 4941492, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9971-959X","authenticated-orcid":false,"given":"Elital","family":"Chass Maurice","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Nur Maymon","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shira","family":"Mandel","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Oholy","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rony","family":"Moses","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Lavon","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orel","family":"Mayost Lev-Ari","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Shachar","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Pulmonology Institute and Adult CF Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Street, Petach Tikva 4941492, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai R.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Pulmonology Institute and Adult CF Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky Street, Petach Tikva 4941492, Israel"},{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niv","family":"Bachnoff","sequence":"additional","affiliation":[{"name":"Omnix Medical Ltd., High-Tech Village, Givat-Ram Campus, Jerusalem 9190401, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Vitiello, A., Blasi, F., Sabbatucci, M., Zovi, A., Miele, F., Ponzo, A., Langella, R., and Boccellino, M. (2024). The Impact of Antimicrobial Resistance in Cystic Fibrosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13061711"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fainardi, V., Neglia, C., Muscar\u00e0, M., Spaggiari, C., Tornesello, M., Grandinetti, R., Argentiero, A., Calderaro, A., Esposito, S., and Pisi, G. (2022). Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis. Children, 9.","DOI":"10.3390\/children9091330"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","unstructured":"GBD 2021 Antimicrobial Resistance Collaborators (2024). Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050. Lancet, 404, 1199\u20131226."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"Forde","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Elfadadny, A., Ragab, R.F., AlHarbi, M., Badshah, F., Ib\u00e1\u00f1ez-Arancibia, E., Farag, A., Hendawy, A.O., De Los R\u00edos-Escalante, P.R., Aboubakr, M., and Zakai, S.A. (2024). Antimicrobial resistance of Pseudomonas aeruginosa: Navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1374466"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nickerson, R., Thornton, C.S., Johnston, B., Lee, A.H.Y., and Cheng, Z. (2024). Pseudomonas aeruginosa in chronic lung disease: Untangling the dysregulated host immune response. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1405376"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Giovagnorio, F., De Vito, A., Madeddu, G., Parisi, S.G., and Geremia, N. (2023). Resistance in Pseudomonas aeruginosa: A narrative review of antibiogram interpretation and emerging treatments. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111621"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.addr.2005.04.002","article-title":"Bacterial resistance to antibiotics: Enzymatic degradation and modification","volume":"57","author":"Wright","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Santana, J.C., Ger\u00f3nimo-Gallegos, A., Mart\u00ednez-Corona, M.B., L\u00f3pez-L\u00f3pez, M., Toscano-Garibay, J.D., Cuevas-Schacht, F., and Coria-Jim\u00e9nez, V.R. (2022). High Rates of Extensively Drug-Resistant Pseudomonas aeruginosa in Children with Cystic Fibrosis. Curr. Microbiol., 79.","DOI":"10.1007\/s00284-022-03048-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00019-18","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yin, C., Alam, M.Z., Fallon, J.T., and Huang, W. (2024). Advances in Development of Novel Therapeutic Strategies against Multi-Drug Resistant Pseudomonas aeruginosa. Antibiotics, 13.","DOI":"10.3390\/antibiotics13020119"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Canesi, L., Auguste, M., Balbi, T., and Prochazkova, P. (2022). Soluble mediators of innate immunity in annelids and bivalve mollusks: A mini-review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1051155"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Talapko, J., Me\u0161trovi\u0107, T., Juzba\u0161i\u0107, M., Tomas, M., Eri\u0107, S., Horvat Aleksijevi\u0107, L., Beki\u0107, S., Schwarz, D., Mati\u0107, S., and Neuberg, M. (2022). Antimicrobial Peptides-Mechanisms of Action, Antimicrobial Effects and Clinical Applications. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101417"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Huan, Y., Kong, Q., Mou, H., and Yi, H. (2020). Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.582779"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, J., Koh, J.J., Liu, S., Lakshminarayanan, R., Verma, C.S., and Beuerman, R.W. (2017). Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design. Front. Neurosci., 11.","DOI":"10.3389\/fnins.2017.00073"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shepperson, O.A., Harris, P.W.R., Brimble, M.A., and Cameron, A.J. (2024). The Antimicrobial Peptide Capitellacin: Chemical Synthesis of Analogues to Probe the Role of Disulphide Bridges and Their Replacement with Vinyl Sulphides. Antibiotics, 13.","DOI":"10.3390\/antibiotics13070615"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Duarte-Mata, D.I., and Salinas-Carmona, M.C. (2023). Antimicrobial peptides\u2019 immune modulation role in intracellular bacterial infection. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1119574"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kang, S.J., Nam, S.H., and Lee, B.J. (2022). Engineering approaches for the development of antimicrobial peptide-based antibiotics. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101338"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Panteleev, P.V., Tsarev, A.V., Safronova, V.N., Reznikova, O.V., Bolosov, I.A., Sychev, S.V., Shenkarev, Z.O., and Ovchinnikova, T.V. (2020). Structure Elucidation and Functional Studies of a Novel \u03b2-hairpin Antimicrobial Peptide from the Marine Polychaeta Capitella teleta. Mar. Drugs, 18.","DOI":"10.3390\/md18120620"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Safronova, V.N., Panteleev, P.V., Sukhanov, S.V., Toropygin, I.Y., Bolosov, I.A., and Ovchinnikova, T.V. (2022). Mechanism of Action and Therapeutic Potential of the \u03b2-Hairpin Antimicrobial Peptide Capitellacin from the Marine Polychaeta Capitella teleta. Mar. Drugs, 20.","DOI":"10.3390\/md20030167"},{"key":"ref_24","unstructured":"Bachnoff, N., Cohen-Kutner, M., Mandel, S., and Nur, N. (2024). Novel Peptide for Treating an Infectious Disease or Condition. (WO 2024\/003890 A1), International Patent."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gagat, P., Ostr\u00f3wka, M., Duda-Madej, A., and Mackiewicz, P. (2024). Enhancing Antimicrobial Peptide Activity through Modifications of Charge, Hydrophobicity, and Structure. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910821"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Agadi, N., Maity, A., Jha, A.K., Chakrabarti, R., and Kumar, A. (2022). Distinct mode of membrane interaction and disintegration by diverse class of antimicrobial peptides. Biochim. Biophys. Acta Biomembr., 1864.","DOI":"10.1016\/j.bbamem.2022.184047"},{"key":"ref_27","first-page":"3919","article-title":"The antimicrobial peptides and their potential clinical applications","volume":"11","author":"Lei","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lopes, B.S., Hanafiah, A., Nachimuthu, R., Muthupandian, S., Md Nesran, Z.N., and Patil, S. (2022). The role of antimicrobial peptides as antimicrobial and antibiofilm agents in tackling the silent pandemic of antimicrobial resistance. Molecules, 27.","DOI":"10.3390\/molecules27092995"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Greco, I., Molchanova, N., Holmedal, E., Jenssen, H., Hummel, B.D., Watts, J.L., H\u00e5kansson, J., Hansen, P.R., and Svenson, J. (2020). Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-69995-9"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mandel, S., Michaeli, J., Nur, N., Erbetti, I., Zazoun, J., Ferrari, L., Felici, A., Cohen-Kutner, M., and Bachnoff, N. (2021). OMN6 a novel bioengineered peptide for the treatment of multidrug resistant Gram negative bacteria. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-86155-9"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Michaeli, J., Mandel, S., Maximov, S., Zazoun, J., Savoia, P., Kothari, N., Valmont, T., Ferrari, L., Duncan, L.R., and Hawser, S. (2022). In vitro and in vivo antimicrobial activity of the novel peptide OMN6 against multidrug-resistant Acinetobacter baumannii. Antibiotics, 11.","DOI":"10.3390\/antibiotics11091201"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e38079","DOI":"10.1016\/j.heliyon.2024.e38079","article-title":"Unveiling mechanisms of antimicrobial peptide: Actions beyond the membranes disruption","volume":"10","author":"Gagandeep","year":"2024","journal-title":"Heliyon"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tajer, L., Paillart, J.C., Dib, H., Sabatier, J.M., Fajloun, Z., and Abi Khattar, Z. (2024). Molecular Mechanisms of Bacterial Resistance to Antimicrobial Peptides in the Modern Era: An Updated Review. Microorganisms, 12.","DOI":"10.3390\/microorganisms12071259"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Narimisa, N., Keshtkar, A., Dadgar-Zankbar, L., Bostanghadiri, N., Far, Y.R., Shahroodian, S., Zahedi Bialvaei, A., and Razavi, S. (2024). Prevalence of colistin resistance in clinical isolates of Pseudomonas aeruginosa: A systematic review and meta-analysis. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1477836"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Islam, T., Tamanna, N.T., Sagor, M.S., Zaki, R.M., Rabbee, M.F., and Lackner, M. (2024). Antimicrobial Peptides: A Promising Solution to the Rising Threat of Antibiotic Resistance. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16121542"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Taheri-Araghi, S. (2024). Synergistic action of antimicrobial peptides and antibiotics: Current understanding and future directions. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1390765"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ghigo, A., Prono, G., Riccardi, E., and De Rose, V. (2021). Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041952"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Taccetti, G., Francalanci, M., Pizzamiglio, G., Messore, B., Carnovale, V., Cimino, G., and Cipolli, M. (2021). Cystic Fibrosis: Recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10030338"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5208\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:14:26Z","timestamp":1760033666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":38,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155208"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155208","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]}}}